Our Product

The prevalence of diabetes is on a rise at an alarming rate. An estimated 285 million people i.e. 6.4% of the world’s adult population suffer from diabetes. The number is expected to grow to 438 million by 2030 that is almost 7.8%
of the adult population.

There is an increasing demand for therapies catering to the treatment of diabetes, globally. In keeping with this demand, Exemed will be manufacturing Metformin HCl for the global markets.

Market focus :
We are going to focus initially on non – regulated markets while our RA team will keep working round the clock to obtain necessary accreditations to make a foray into the regulated markets of the US and EU.